As U.S. ditches diversity in clinical trials, all eyes on Europe
Racial health inequality manifests in many ways — be it discriminatory treatment or higher death rates — but one glaring disparity kicks in at the get-go with the testing of all drugs, medical devices and treatments pre-launch.
Studies show that ethnic minorities are far less likely to volunteer for such trials, a fact that health experts put down to mistrust of the health system, fear and misinformation.
So when the pandemic showed that Black, Asian, Hispanic and other minority communities were worse hit by COVID-19 than white populations, governments, researchers and pharmaceutical firms all committed to greater diversity in future clinical trials.
Recruiting more volunteers from different genders, sex, ages and ethnic groups is key to treating diseases more effectively and addressing disparities, health experts say.
The United States was the first country to require companies to test medicines and devices in diverse populations when it brought in draft guidance in 2022, due to be finalized this year.
"Diversity in clinical trials is not about an ideological position. It's about scientific accuracy and medical progress," said Joshua Sharfstein, a former top official at the U.S. regulatory body the Food and Drug Administration (FDA).
But that progress now hangs in limbo as U.S. President Donald Trump's administration guts staff and funding from health departments, and scrubs diversity, equity and inclusion (DEI) policies from federal agencies.
Demonstrators hold up signs while protesting outside the Center for Disease Control, in Atlanta, after the Trump administration began mass layoffs this month. |
reuters
The FDA's Diversity Action Plan draft guidance was among several U.S. government webpages removed in January due to "gender ideology" before a court order reinstated it.
Researchers and health campaigners say it is unclear whether the United States will now implement the diversity guidance, as mandated by the 2022 Food and Drug Omnibus Reform Act.
The FDA and the U.S. Department of Health and Human Services, which oversees the agency, did not immediately respond to requests for comment.
The government on Tuesday began cutting 10,000 jobs at public health agency the Centers for Disease Control and Prevention, the FDA, and the National Institutes of Health, the leading funder of global medical research.
"It's a very chaotic situation and one hopes for the best and one fears for the worst," said physician Robert Steinbrook, director of health research at U.S. advocacy group Public Citizen.
"If the FDA were to abandon the scientific progress that has been made because of 'gender ideology' or other concepts which are quite ambiguous... it would be a big step backwards," he told the Thomson Reuters Foundation.
Samantha Artiga, director of racial equity at U.S. health policy group KFF, said positive post-COVID initiatives could lose momentum under Trump.
"We're likely to continue to see under-representation of groups in trials, particularly people of colour and women and other historically under-served groups," she said.
A 2022 Lancet paper analyzing 20 years of studies showed that less than half of all U.S.-based trials included race and ethnicity data.
Despite Black patients representing 21% of COVID-19 deaths, they made up only 3% of U.S. vaccine trials, the study reported.
Mayur Murali, a researcher at Imperial College London, found similar trends in a 2023 paper studying British vaccine take-up.
Asian volunteers made up 5.8% of all the COVID-19 vaccine trials analyzed and 1% of Black people were included despite these populations having higher mortality rates than white people, according to official data.
Fear and mistrust of the health system contributed to their exclusion from the trials, said Murali.
"With COVID-19 vaccine hesitancy for example, there was a lot of mistrust amongst ethnic minority communities and a lot of it was to do with misinformation and feeling locked out."
According to a 2024 survey of over 8,000 people by research group Ipsos, 41% of ethnic minorities were willing to volunteer in a trial compared to 61% of white respondents, citing fear of side effects and mistrust of pharmaceutical companies.
"If you can make that process transparent. ... I think people would be very happy to be involved," Murali said.
With the United States turning its back on diversity initiatives, researchers hope Britain and Europe will step up.
"I'm worried that the U.S. is not talking about equity, diversity and inclusion anymore," said Sonia Anand, a professor of medicine and epidemiology at McMaster University in Canada.
"I really hope that these other governments will continue along the path to promoting the importance of equitable inclusion into clinical trials."
There are promising signs.
The World Health Organization last year released global guidance to improve diversity in trials.
In Europe, a consortium of 73 private and public organizations launched Research in Europe and Diversity Inclusion (READI) in January to tackle the under-representation.
British drugmaker GSK, which is part of READI, said the demand to conduct trials that are representative of the different populations and countries they work in remained high.
Pfizer and Moderna, makers of COVID-19 vaccines, said they were committed to boosting diversity in clinical trials.
In January, Britain began consulting on how best to reflect diverse ethnicity, age, sex and gender in clinical research.
Naho Yamazaki, who is spearheading the draft guidance at Britain's Health Research Authority, said it was crucial the guidance truly removes barriers and was not just a "tick box" exercise.
"Reducing health disparity requires far more than just equitable representation in clinical research. It's got to be a global effort ultimately. It's not a quick thing, but the momentum is here," Yamazaki said.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yomiuri Shimbun
4 days ago
- Yomiuri Shimbun
Experimental Surgical Robot Performs Gallbladder Procedure Autonomously
An experimental AI-guided robot can autonomously perform a delicate, complicated phase of a common gallbladder operation, marking a major step toward automated medical procedures, researchers said on July 9. Existing surgical robots are remotely controlled by surgeons. The new system uses artificial intelligence to make independent decisions and adapts to unexpected complications during operations, said Axel Krieger of Johns Hopkins University in Baltimore, who led the research. He likened it to an autonomous vehicle that can 'navigate any road, in any condition, responding intelligently to whatever it encounters.' 'This advancement moves us from robots that can execute specific surgical tasks to ones that truly understand surgical procedures,' he said. The SRT-H robot was trained via an AI framework known as language-guided imitation learning, using videos of surgeons performing gallbladder removal surgeries on pig cadavers, the researchers reported in Science Robotics. The robot was tested on eight varying sets of pig gallbladders and livers that had been removed from the animals. Separating the gallbladder from the liver takes several minutes and involves 'diverse tool use, including grabbing, clipping, and cutting — skills common in real surgical procedures,' along with decision-making and adaptation, the researchers said. The pig organs and blood vessels in the tests varied widely in appearance and anatomy, 'mirroring the diversity encountered in human surgeries,' they said. While the robot achieved 100% accuracy in the surgeries, it took longer to perform the work than a human surgeon. Commercially available surgical robots include Intuitive Surgical's da Vinci Surgical System, which has been used in over 12 million procedures globally since receiving FDA approval in 2000. Unlike SRT-H, the da Vinci system relies entirely on human surgeons to control its movements remotely. The global surgical robotics market is approaching $10 billion annually with about 2.7 million robotic procedures performed in 2024, Baird analyst David Rescott estimated. Eventually, autonomous surgical robots could help address surgeon shortages, minimize human error and provide consistent, high-quality care in underserved regions, the researchers said. The research was supported by the Advanced Research Projects Agency for Health, the National Science Foundation and the National Institutes of Health.
NHK
5 days ago
- NHK
Trump diagnosed with venous insufficiency, but not serious health problem
0The White House says US President Donald Trump has received a medical checkup, and that he has venous insufficiency, but remains in "excellent health." In a news conference Thursday, Press Secretary Karoline Leavitt said Trump was diagnosed with chronic venous insufficiency. Leavitt said he underwent a comprehensive examination after noticing swelling in his lower legs in recent weeks. She said the condition is common in individuals over the age of 70. Trump turned 79 in June. Leavitt also said Trump's bruises on the back of his hand was caused by frequent handshaking, and the use of aspirin, which he takes for prevention against cardiovascular disease. She said the exam results showed "no signs of heart failure, renal impairment or systemic illness." Leavitt also released the physician's memorandum of the diagnosis. She said, "The President remains in excellent health, which I think all of you witness on a daily basis here." She stressed that Trump wanted to release the memorandum "in the effort of transparency." Former US President Joe Biden, who was 78 when he was sworn in, announced in May that he has been diagnosed with prostate cancer, which had spread to his bones. But Trump questioned the timing of the announcement as it was made after Biden had already left office.
Japan Times
5 days ago
- Japan Times
U.S. health department hands over Medicaid personal data to ICE
The U.S. health department is giving Immigration and Customs Enforcement (ICE) officials access to the personal data of 79 million Medicaid enrollees to help them track down immigrants who may not be living legally in the country, it said on Thursday. Giving ICE access to the personal data of Medicaid enrollees marks an escalation in U.S. President Donald Trump's hard-line immigration policies. It may also raise privacy concerns under the Health Insurance Portability and Accountability Act, known as HIPAA. A Department of Health and Human Services spokesperson said sharing data between the Centers for Medicare and Medicaid Services (CMS) and the Department of Homeland Security (DHS), which oversees ICE, fell within the department's legal authority. "With respect to the recent data sharing between CMS and DHS, HHS acted entirely within its legal authority — and in full compliance with all applicable laws — to ensure that Medicaid benefits are reserved for individuals who are lawfully entitled to receive them," the spokesperson said. A spokesperson for the Department of Homeland Security said the department was exploring an initiative with CMS to ensure people living in the country illegally do not receive Medicaid benefits. The agreement was first reported earlier on Thursday by the Associated Press, which said it was signed on Monday. The Medicaid health program for low income people is jointly funded by the federal government and states. Immigrants who are in the U.S. illegally are not eligible for Medicaid under federal law, but 14 states and the District of Columbia provide coverage for eligible children regardless of immigration status, and seven states and the district do so for adults. "CMS is aggressively cracking down on states that may be misusing federal Medicaid funds to subsidize care for illegal immigrants. This oversight effort — supported by lawful interagency data sharing with DHS — is focused on identifying waste, fraud, and systemic abuse," the HHS spokesperson said. The spokesperson did not address questions from Reuters on the type of data being shared or on how HHS would ensure HIPAA protections are upheld. The AP, citing a copy of the data sharing agreement, said the data included home addresses and ethnicities. The agreement is the latest in a series of moves by the health department in support of the Trump administration's immigration crackdown and comes a week after it widened its interpretation of a law banning most immigrants from receiving federal public benefits.
